AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04251234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light intensity, ~30 lux
Description: \~30 lux compared to very dim light baseline condition \<1 lux
Study NCT04251234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline light intensity, <1 lux
Description: Very dim light condition
Study NCT02266121 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
Study NCT02266121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
Study NCT00187486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
Study NCT00187486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar
Description: Temodar 200 mg/m\^2/day x 5 days every 28 days
Study NCT00187486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
Study NCT01184794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levobupivacaine
Description: 40 ml over 48 hours
Study NCT01184794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: 40 ml over 48 hours
Study NCT00121602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa
Description: Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
Study NCT00121602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
Study NCT00928603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Cryoablation
Description: Cryotherapy is administered via the perineum under ultrasound guidance by third-generation 17-gauge cryoprobes using gas and thermal couples. Under transrectal ultrasound guidance cryoprobes are placed approximately 1 cm apart and within 5 mm of the capsule on the side of tumor. The extent of freezing was limited to the area or lobe of the gland with histologically proved tumor.
Study NCT00759031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Monofluorophosphate
Description: Brush teeth and evaluate plaque score after one use of the study toothpaste
Study NCT03407027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadratus triamcinolone
Description: 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
Study NCT01216787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Study NCT00759031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Fluoride/Copolymer
Description: Brush teeth and evaluate plaque score after one use of the study toothpaste
Study NCT02662296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02662296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Given PO
Study NCT01216787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT01216787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT01216787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01649960 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rapamycin
Description: Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
Study NCT01283035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01283035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01806766 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic on Ceramic bearing
Description: cementless Total Hip Arthroplasty with Ceramic on ceramic bearing
Study NCT01806766 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic on Highly crosslinked polyethylene bearing
Description: Cementless Total Hip Arthroplasty with Ceramic on Highly crosslinked polyethylene bearing
Study NCT05404295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Umbilical cord blood platelel lysate gel
Description: For the treatment group, a gel from Umbilical cord blood platelel lysat will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area.
Study NCT03407027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gluteus triamcinolone
Description: 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
Study NCT04856501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PALS intervention condition
Description: The Play and Learning Strategies (PALS) intervention provides parents with behaviors that, collectively, are known as a responsive parenting style. Four constructs make up this responsive parenting style: 1) contingent responsiveness, (responses are conditionally linked to the child's signals) 2) warm sensitivity (high levels of affection and understanding of child states), 3) maintaining vs. redirecting attention, and 4) verbal scaffolding (providing child appropriate language supports). Parents assigned to this intervention will be paired with a coach who will guide them through the program over the course of 9 weekly sessions. The intervention (ePALS) will be implemented via an internet adaptation through the Children's Learning Institute's ENGAGE platform. However, ePALS could easily be adapted for other platforms and accessed with any web-enabled device.
Study NCT04856501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Families assigned to the control condition will be provided with a website with information corresponding to milestones of toddler development. Control families will be asked to review that week's materials before the each of the 9 weekly coach calls. The active control condition serves three important purposes: 1) Maintains an active line of communication and accurate contact records for Post-test 1 and Post-test 2 session scheduling; 2) Masks participant's awareness of intervention vs. control assignment; and 3) Approximates communication with intervention staff such that results showing ePALS effects are attributable to intervention rather than regular communication with an interventionist.
Study NCT02113553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin administered once every 28 days in addition to chemotherapy
Study NCT03407027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quadratus without triamcinolone.
Description: 10ml of levobupivacaine 0,25%.
Study NCT05404295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical cord blood platelel lysate gel
Description: For the treatment group, a gel from Umbilical cord blood platelel lysat will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area.
Study NCT01129609 — intervention group
Intervention type: DEVICE
Intervention: Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System
Description: All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin intravenous
Description: 85 mg/m² in intravenous. 1 cycle each 15 days
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU bolus
Description: 5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU bolus
Description: 5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: 400 mg/m² in intravenous
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid
Description: 400 mg/m² in intravenous
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin intra-arteriel
Description: 85 mg/m² in intra-arterial. 1 cycle each 15 days
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg at each cycle in intravenous
Study NCT03333109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: 70 mg/mL pre-filled syringe administered subcutaneously
Study NCT03369340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 1
Description: 2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Study NCT01243112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Lidocaine with Epinephrine (1:100,000)
Description: 0.2ml Intradermal injection once.
Study NCT01243112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine with Epinephrine (1:200,000)
Description: 0.2ml Intradermal injection once.
Study NCT01243112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)
Description: 0.2ml Intradermal injection once.
Study NCT01243112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)
Description: 0.2ml Intradermal injection once.
Study NCT04990700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial rib resection
Description: 1 cm partial rib resection during thoracotomy opening
Study NCT03594058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solabegron modified release tablets, low dose
Description: Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg at each cycle in intravenous
Study NCT03594058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solabegron modified release tablets, high dose
Description: Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
Study NCT03333109 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in pre-filled syringe administered subcutaneously
Study NCT01447706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 (SAR256212) (IV)
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU continuous
Description: 2400 mg/m² intravenously over 46 hours
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU continuous
Description: 2400 mg/m² intravenously over 46 hours
Study NCT01129765 — intervention group
Intervention type: DEVICE
Intervention: Use of an automatic nasal irrigator/aspirator
Description: After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
Study NCT01202188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol and glycopyrronium (QVA149)
Description: Capsules for inhalation delivered via SDDPI.
Study NCT01202188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycopyrronium (NVA237)
Description: Capsules for inhalation delivered via SDDPI.
Study NCT01447706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard dosing Paclitaxel (IV)
Study NCT01447706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Standard dosing Paclitaxel (IV)
Study NCT01202188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indacaterol (QAB149)
Description: Capsules for inhalation delivered via SDDPI.
Study NCT02198300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty with stent implantation
Study NCT02198300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty with stent implantation
Study NCT02198300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual antipletlet therapy (DAPT)
Description: DAPT given to each patient before stent implantation
Study NCT02198300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antipletlet therapy (DAPT)
Description: DAPT given to each patient before stent implantation
Study NCT01084941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention group
Description: Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
Study NCT01084941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
Study NCT03594058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
Study NCT00002825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT01202188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: Capsules for inhalation delivered via HandiHaler® device.
Study NCT01202188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo to match capsules for inhalation delivered via SDDPI.
Study NCT01324050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered psychodynamic therapy for depression
Description: This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
Study NCT01324050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered therapist support
Description: This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m² intravenous
Study NCT02885753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 150 mg/m² intravenous
Study NCT03937310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next-generation sequencing of swabs collected during surgery
Description: Traditional swabs for culturing as well as swabs for NGS testing will be collected
Study NCT03767530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mibo Thermoflo
Description: Thermal therapy with Mibo Thermoflo for 11 minutes per eye, during each session.
Study NCT03767530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm compresses and eyelid massage
Description: Warm compresses plus eyelid massage 2 times per day 11 minutes per eye.
Study NCT00281255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Study NCT03369340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 2
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Study NCT03369340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 3
Description: 1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Study NCT00281255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Study NCT00281255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dobutamine
Study NCT01121822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular
Study NCT02584673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.
Description: The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
Study NCT02097576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline mixed with Manuka Honey
Description: Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
Study NCT02097576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NeilMed Saline Sinus Rinse
Description: Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
Study NCT05295511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recreational Team Handball programme
Description: All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).
Study NCT03369340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 4
Description: 2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Study NCT01430949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation of Paroxysmal Atrial Fibrillation
Description: Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
Study NCT02100813 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LEO 43204
Study NCT02100813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 43204
Study NCT02100813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo